Editorial review
16 September 2026: what we checked
This review compared the site with evidence available by 16 September 2026, following the 27 August baseline. The notes below record the checks, corrections, sources and unresolved limits for individual items and trials.
Review depth varies. A current registry check can establish registered status, dates and eligibility; it does not verify every historical outcome or establish treatment approval or local access. Some papers were available only as abstracts or metadata. Sponsor announcements and conference reports are identified in the notes and carry different limits from peer-reviewed results.
This is an AI-assisted editorial review, not independent clinical certification. A review date or an unchanged record does not certify every claim. Read the scope and limits alongside the sources; scores remain editorial judgments.
441 of 441 current records have dated review notes. Multiple reviews of one record are shown together. Existing page review dates have not been advanced merely to match this pass.
Find a record · Read the full review reports · Methodology · Changelog
Review notes by record
1–40 of 441 matching records (441 total). A note describes scope, not a verification rating.
- Abatacept (CTLA4-Ig) — review notes →
Item · 1 review note · Evidence page
- Abatacept (CTLA4-Ig) to delay type 1 diabetes in at-risk relatives — review notes →
Trial · 1 review note · Evidence page
- Abbott continuous glucose/ketone monitoring and DKA occurrence — review notes →
Trial · 1 review note · Evidence page
- Abbott Libre Duo — review notes →
Item · 1 review note · Evidence page
- Abbott Lingo — review notes →
Item · 1 review note · Evidence page
- ACCESS-T1D: Florida relatives and autoimmune-risk screening — review notes →
Trial · 1 review note · Evidence page
- Accu-Chek SmartGuide — review notes →
Item · 1 review note · Evidence page
- Accu-Chek Solo micropump — review notes →
Item · 1 review note · Evidence page
- ADAPT: MiniMed 780G advanced hybrid closed-loop vs injections + flash CGM — review notes →
Trial · 1 review note · Evidence page
- Adaptive platform trial: golimumab in stage 1 (presymptomatic) T1D — review notes →
Trial · 1 review note · Evidence page
- Adjunct therapy to reduce iatrogenic hyperinsulinemia in T1D — review notes →
Trial · 1 review note · Evidence page
- ADJUST-T1D: semaglutide with AID in adults with obesity — review notes →
Trial · 1 review note · Evidence page
- AI bolus priming added to AIDANET — review notes →
Trial · 1 review note · Evidence page
- AI-assisted remote insulin-pump optimisation in T1D — review notes →
Trial · 1 review note · Evidence page
- AID before and during pregnancy in T1D — review notes →
Trial · 1 review note · Evidence page
- AID beyond glucose metrics — review notes →
Trial · 1 review note · Evidence page
- AIDANET at Home: fully closed-loop vs hybrid modes — review notes →
Trial · 1 review note · Evidence page
- AIDANET fully closed-loop algorithm — review notes →
Item · 1 review note · Evidence page
- AiDAPT: Automated Insulin Delivery in Pregnancy with Type 1 Diabetes — review notes →
Trial · 1 review note · Evidence page
- AIMING: AID during labor and delivery in T1D — review notes →
Trial · 1 review note · Evidence page
- Ain Shams adipose-derived insulin-producing cells — review notes →
Item · 1 review note · Evidence page
- AL1GN: long-term outcomes of teplizumab in routine care — review notes →
Trial · 1 review note · Evidence page
- Alefacept (CD2 memory T-cell targeting) — review notes →
Item · 1 review note · Evidence page
- Allogeneic CD7-CAR-T (RD13-02) — review notes →
Item · 1 review note · Evidence page
- Allogeneic CD7-targeted CAR-T for T1D — review notes →
Trial · 1 review note · Evidence page
- Allogeneic regenerative islet transplantation for brittle T1D — review notes →
Trial · 1 review note · Evidence page
- Allogenic islet cell transplantation at University of Chicago — review notes →
Trial · 1 review note · Evidence page
- AndroidAPS — review notes →
Item · 1 review note · Evidence page
- Anti-IL-21 antibody + liraglutide — review notes →
Item · 1 review note · Evidence page
- Anti-IL-21 plus liraglutide in recent-onset T1D — review notes →
Trial · 1 review note · Evidence page
- Argus 2.0 CGM adoption study — review notes →
Trial · 1 review note · Evidence page
- ASITI-201 (proinsulin peptide / calcitriol liposomes) — review notes →
Item · 1 review note · Evidence page
- ASITI-201 Phase 1 in stage 3 T1D (Queensland) — review notes →
Trial · 1 review note · Evidence page
- ASK (Autoimmunity Screening for Kids) — review notes →
Item · 1 review note · Evidence page
- ASK: free autoimmunity screening for US children and adults — review notes →
Trial · 1 review note · Evidence page
- Aspect Biosystems bioprinted islet tissue (ex-Novo Nordisk platform) — review notes →
Item · 1 review note · Evidence page
- AT247 ultra-rapid insulin — review notes →
Item · 1 review note · Evidence page
- AT278 (U500 ultra-rapid insulin aspart) — review notes →
Item · 1 review note · Evidence page
- Australian T1D National Screening Pilot — review notes →
Item · 1 review note · Evidence page
- Autologous CD6-CAR regulatory T cells — review notes →
Item · 1 review note · Evidence page
Full review reports
These are the underlying dated ledgers, including their review methods and limitations. Their record counts overlap where a study received more than one review.
- Preventing and curing evidence review — 16 September 2026 → (91 records)
- Thriving evidence review — 16 September 2026 → (121 records)
- Baseline trial evidence review: A–H → (82 records)
- Baseline trial evidence review: M–S → (59 records)
- Primary-agent trial review — 16 September 2026 → (91 records)
- Selected cell-therapy and adjunct trial review — 16 September 2026 → (8 records)
- Selected historical trial audit → (5 records)